YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H released its earnings results on Aug 30, 2024. The company reported HK$0.829 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.829.

Is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H overvalued?

According to Wall Street analysts YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H pay dividends?

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H pays a Annually dividend of HK$0.113 which represents an annual dividend yield of N/A. See more information on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H dividends here

What is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s EPS estimate?

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H have?

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H has 653,767,700 shares outstanding.

What happened to YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price movement after its last earnings report?

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H reported an EPS of HK$0.829 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.17%.

Which hedge fund is a major shareholder of YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:1558

---

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Stock Smart Score

Unlock Smart Score

Analyst Consensus

Moderate Buy

Average Price Target:
HK$12.60 (31.94% Upside)

Technicals

Fundamentals

Return on Equity

21.26%

Trailing 12-Months

Asset Growth

-7.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H

Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic and cardiovascular diseases. The company's major revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Xinhaining, and Xining which cure diseases such as hypertension and allergy.

---

1558 Stock 12 Month Forecast

Average Price Target

HK$12.60

▲(31.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"HK$7","10":"HK$10","13":"HK$13","8.5":"HK$8.5","11.5":"HK$11.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$12.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$12.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$12.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,8.5,10,11.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.3,9.553846153846154,9.807692307692308,10.061538461538461,10.315384615384616,10.569230769230769,10.823076923076924,11.076923076923077,11.330769230769231,11.584615384615384,11.838461538461539,12.092307692307692,12.346153846153847,{"y":12.6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.3,9.553846153846154,9.807692307692308,10.061538461538461,10.315384615384616,10.569230769230769,10.823076923076924,11.076923076923077,11.330769230769231,11.584615384615384,11.838461538461539,12.092307692307692,12.346153846153847,{"y":12.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.3,9.553846153846154,9.807692307692308,10.061538461538461,10.315384615384616,10.569230769230769,10.823076923076924,11.076923076923077,11.330769230769231,11.584615384615384,11.838461538461539,12.092307692307692,12.346153846153847,{"y":12.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.29,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.36,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.3,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.48,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.24,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.68,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.96,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.9,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.99,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.22,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.66,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.66,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Viva Biotech Holdings

―

2377

China Boqi Environmental (Holding) Co., Ltd.

―

3692

Hansoh Pharmaceutical Group Company Limited

―

Compare HK:1558 Stocks >

Best Analysts Covering 1558

1 Year

Laurence TamMorgan Stanley

1 Year Success Rate

1/2 ratings generated profit

1 Year Average Return

+8.95%

reiterated a buy rating 28 days ago

Copying Laurence Tam's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +8.95% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing